Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995). 1986

G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin

Inappropriate hypersecretion of TSH was investigated in a 25 year old man whose hyperthyroidism had relapsed 4 years after subtotal thyroidectomy. Serum TSH levels were further increased by both TRH and metoclopramide and were partially suppressed by triiodothyronine (120 micrograms/day). The serum alpha-subunit: TSH molar ratio was less than 1.0, and computerised axial tomography showed no evidence of a pituitary tumour. These features are characteristic of inappropriate TSH secretion due to thyrotroph resistance to thyroid hormones. A long-acting somatostatin analogue (SMS 201-995), 50 micrograms injected sc twice-daily for three days, suppressed TSH levels and nearly normalised thyroid hormone levels. Somatostatin analogues may be therapeutically useful in thyrotoxicosis due to non-tumoural inappropriate TSH hypersecretion.

UI MeSH Term Description Entries
D006980 Hyperthyroidism Hypersecretion of THYROID HORMONES from the THYROID GLAND. Elevated levels of thyroid hormones increase BASAL METABOLIC RATE. Hyperthyroid,Primary Hyperthyroidism,Hyperthyroidism, Primary,Hyperthyroids
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013004 Somatostatin A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal. Cyclic Somatostatin,Somatostatin-14,Somatotropin Release-Inhibiting Hormone,SRIH-14,Somatofalk,Somatostatin, Cyclic,Somatotropin Release-Inhibiting Factor,Stilamin,Somatostatin 14,Somatotropin Release Inhibiting Factor,Somatotropin Release Inhibiting Hormone
D013963 Thyroid Hormones Natural hormones secreted by the THYROID GLAND, such as THYROXINE, and their synthetic analogs. Thyroid Hormone,Hormone, Thyroid,Hormones, Thyroid
D013972 Thyrotropin A glycoprotein hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Thyrotropin stimulates THYROID GLAND by increasing the iodide transport, synthesis and release of thyroid hormones (THYROXINE and TRIIODOTHYRONINE). Thyrotropin consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the pituitary glycoprotein hormones (TSH; LUTEINIZING HORMONE and FSH), but the beta subunit is unique and confers its biological specificity. Thyroid-Stimulating Hormone,TSH (Thyroid Stimulating Hormone),Thyreotropin,Thyrotrophin,Hormone, Thyroid-Stimulating,Thyroid Stimulating Hormone
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995

Related Publications

G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
December 1989, Scandinavian journal of gastroenterology,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
July 1987, The Korean journal of internal medicine,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
January 1989, The Journal of clinical endocrinology and metabolism,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
October 1988, Endocrinologia japonica,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
June 1985, Experientia,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
February 1989, Harefuah,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
December 1986, Annals of internal medicine,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
February 1992, Alimentary pharmacology & therapeutics,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
January 1985, The New England journal of medicine,
G Williams, and M Kraenzlin, and L Sandler, and J Burrin, and A Law, and S Bloom, and G F Joplin
May 1990, Clinical endocrinology,
Copied contents to your clipboard!